EvoGenix to collaborate on antibody research with CSL

By E. Janene Geiss

Philadelphia, June 1 - EvoGenix Ltd. said Thursday that it had entered into a technology collaboration with CSL Ltd. to generate superior antibodies that are more effective as human therapeutics.

EvoGenix said it will apply its proprietary technologies to antibody products selected by CSL from its pipeline, according to a company news release.

CSL said will have the right to commercialize the products, with EvoGenix to receive royalty payments as therapeutics emerging from the collaboration reach the market.

Under the agreement, EvoGenix said it will receive research payments to carry out work on CSL's products.

Each project carries a success payment for achievement of project goals as well as milestone payments as the product advances through the subsequent stages of clinical testing and regulatory approval, officials said.

The agreement marks the growing interest by Australian health care companies in the dynamic antibody sector, which is seen as the source of many of the blockbuster drugs of the future, officials said.

The agreement is the second major collaboration entered by EvoGenix to exploit its proprietary antibody development technologies.

The first was signed with GlaxoSmithKline late last year. EvoGenix said it expects to use its proprietary technologies in additional selected relationships over the next two to three years.

EvoGenix is a Sydney, Australia, biotechnology company that focuses on development of antibody therapeutics.

CSL is a Melbourne, Australia, biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.